Monday 5 November 2018

Reuters Health Report: Lilly says diabetes drug Trulicity reduces heart risks in trial

Reuters.com Newsletter

Lilly says diabetes drug Trulicity reduces heart risks in trial

Eli Lilly and Co said on Monday that its top-selling diabetes drug Trulicity significantly reduced the risk of heart attack, stroke and heart-related death in a broad range of people with type 2 diabetes, according to results of a large clinical trial.

China battles to control African swine fever as it reports 50th case

China confirmed a new case of African swine fever on Monday, in southern Hunan province, marking the 50th outbreak of the highly contagious disease in the world's top pork producer.

Novartis abandons effort for U.S. approval of biosimilar rituximab

Novartis International AG said on Friday that its Sandoz division is abandoning an effort to gain U.S. regulatory approval for a biosimilar of rituximab, a medication used to treat certain cancer and rheumatoid arthritis.

FDA approves Pfizer's treatment for certain lung cancer patients

Pfizer Inc said on Friday the U.S. Food and Drug Administration has approved its lung-cancer treatment for patients with a specific gene mutation who had been previously treated for an aggressive form of the disease.

FDA panel recommends Sage's postpartum depression treatment

An advisory panel to the U.S. Food and Drug Administration on Friday recommended Sage Therapeutics Inc's experimental treatment for postpartum depression, saying the benefits of the drug outweighed risks.

FDA approves AcelRx Pharma's opioid pain drug

The U.S. Food and Drug Administration on Friday approved AcelRx Pharmaceuticals Inc's opioid-based treatment for pain to be used under strict medical supervision, with the agency's chief highlighting reasons for the approval in a rare move.

Pharmacies still blocking U.S. teens looking for emergency contraception

(Reuters Health) - Teens seeking to buy emergency contraception at pharmacies continue to face significant roadblocks, a new U.S. study suggests.

Tall people may be more prone to varicose veins

(Reuters Health) - Standing above the crowd puts people at greater risk of developing varicose veins, a large genetic study suggests.

Trevena opioid painkiller fails to win FDA approval, shares plunge

Trevena Inc shares plunged 45 percent on Friday after the U.S. Food and Drug Administration declined to approve its opioid injection for managing acute pain, citing inadequate safety data.

E-therapy may help ease insomnia

(Reuters Health) - People with insomnia who receive a digitized version of cognitive behavioral therapy (CBT) as part of their treatment may find more symptom relief than those who only receive tips to improve their sleep routines, a recent experiment suggests.

Inconsistent heart surgery ratings may confuse patients

(Reuters Health) - Publicly-available ratings of U.S. hospital quality for heart surgery vary so widely from one another they may be more confusing than helpful for patients trying to pick the best place to have a procedure, researchers say.

Related Videos

Paraplegics walk again with spinal implant

Traitor or agent: the choice for Ukraine's priests

Introducing the all-new
Reuters News app

The new Reuters News app is here, redesigned from the ground up to fit your busy life.

Get it now on iOS